Drugs / KR23248
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07585383 | May → Nov 2026 expected | schizophrenia | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KR23248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07585383 ↗ |
| Route | Oral | “single oral dose of KR23248” NCT07585383 ↗ |